Disclaimer: The materials on this website do not constitute legal advice. You should consult with an attorney before acting on or conveying any interpretation of these materials.
These agreements are available as starting points for negotiations with particular research sponsors for clinical and, in some cases, preclinical or other types of studies. Faculty members are welcomed to use these documents as starting points; however, all contracts must be processed through the appropriate office at each UT institution. 
Contact Marc Vockell or Sheila Kadura in OGC for copies of standard contracts specific to UT institutions.

Active Agreements

Abbott Laboratories

• Master Clinical Study Agreement (OGC#189530)
  Effective 6/30/2020 - 6/30/2025

AbbVie Inc.

• Master Confidential Disclosure Agreement
  Effective 8/21/2024 - 8/21/2029
• Master Clinical Study Agreement 
  Effective 3/18/2022 - 03/18/2027
  • MCSA Amendment #1
    Effective 12/21/2022 (SOW Template)

Alexion Pharmaceuticals, Inc.

• Master Clinical Study Agreement
  Effective 4/19/2023 - 4/19/2028

Amgen, Inc. 

• General Clinical Trial Agreement
  Effective 9/23/2022 (evergreen)
• Master Mutual Confidential Disclosure Agreement (OGC#183500)
  Effective 4/30/2020 - 4/30/2027
• Master Materials and Funding Agreement
  Effective 6/28/2007 (evergreen)
  • MMFA Amendment #1
    Effective 6/28/2007
• Master Clinical Study Agreement with Amendments #1 and #2 
  Effective 12/27/2000 until terminated by written agreement
  • MCSA Amendment #2
    Effective 2/22/2010 (add Sections 21, 22)
  • MCSA Amendment #1
    Effective 3/1/2006 (exclude UTMDACC; extend until terminated by written agreement)

Army Research Laboratory (ARL)

• Master Cooperative Research and Development Agreement (CRADA) (OGC#185215)
  Effective 5/30/2014 - 5/30/2024
  • CRADA Amendment #2 
    Effective 11/16/2018 (extend term to 5/30/2024)
  • CRADA Amendment #1
    Effective 9/1/2015 (add UTRGV)

Astellas Pharma US, Inc. / 
Astellas Pharma Global Development, Inc.

• Master Clinical Trial Agreement
  Effective 10/18/2021 - 10/18/2026

AstraZeneca Pharmaceuticals LP /
AstraZeneca LP/AstraZeneca Pharmaceuticals LP

• Master Mutual Confidentiality Agreement (OGC#173119)
  Effective 2/27/2017 - 2/27/2027
• Master Clinical Study Agreement (OGC#s 155832, 167526, 167750, 176991, 184879; 194491)
  Effective 3/15/2015 - 3/16/2025
  • MCSA Amendment #2
    Effective 3/15/2020 (remove Clinical Trial Xpress; extend to 3/16/2025)
  • MCSA Amendment #1 
    Effective 9/1/2017 (add Clinical Trials Xpress and UTRGV)

BeiGene, USA, Inc.

• Master Clinical Study Agreement
  Effective 02/12/2024 - 02/12/2029

BoehringerIngelheim Pharmaceuticals, Inc.

• Master Clinical Trial Agreement
  Effective 1/17/2023 - 1/17/2028
  • MCTA Amendment #1
    Effective 1/17/2023 (replaced Trial Participant Injury paragraph)
• Master Confidential Disclosure Agreement (OGC#203208)
  Effective 11/1/2021 - 11/1/2026

Bristol-Myers Squibb

• Master Confidentiality Agreement
  Effective 10/12/2020 - 10/12/2027
• Sponsor Initiated Master Clinical Trial Agreement
  Effective 4/7/2021 - 4/7/2026
• Master Investigator-Sponsored Research Agreement (OGC#s  159139, 178032, 178368)
  Effective 11/5/2018 - 11/5/2028
  • Master ISR Amendment #1 (OGC#210960)
    Effective 07/26/2023 (add UT Dallas)

Chugai Pharma USA, Inc.

• Master Non-Disclosure and Confidentiality Agreement (MNDA)
  Effective 8/7/2024 - 8/7/2029

Genentech, Inc.

• Investigator Initiated Master Research Payment and Supply Agreement (OGC#177298)
  Effective 5/1/2018 - 4/30/2028
• Sponsor Initiated Master Clinical Research Agreement (OGC#186361, 155191)
  Effective 1/16/2015 - 1/15/2025

Genzyme Corporation (see Sanofi)
 

Howmedica Stryker

• Master Research Agreement (OGC#203202)
  Effective 7/25/2022 - 7/25/2027

Janssen Research & Development, LLC

• Master Mutual Confidentiality Agreement
  Effective 05/18/2021 - 05/28/2026
• Sponsor Initiated Master Clinical Trial Agreement
  Effective 10/14/2020 - 10/14/2025

Lilly USA, LLC

• Master Clinical Trial Agreement (OGC#171577)
  Effective 12/5/2017 - 12/5/2022
  • MCTA Amendment #1
    Effective 12/5/2017(extend to 12/5/2025)

Merck Sharp & Dohme Corp. f/k/a 
Schering Corporation

• Master Clinical Trial Research Agreement
  Effective 6/15/2009 - 6/15/2029
  • MCTRA Amendment #3
    Effective 9/20/2022 (replace Article 7B and Article 13)
  • MCTRA Amendment #2 (OGC#186263)
    Effective 8/23/2021 (remove UTMDACC; add UTRGV)
  • MCTRA Amendment #1
    Effective 5/9/2013 (address Schering name change)

Novartis Pharmaceuticals Corporation

• Mutual Master Confidential Disclosure Agreement (OGC#181144)
  Effective 1/13/2021 - 1/13/2026
• Sponsor-Initiated Master Clinical Trial Agreement (OGC#119052) Effective 5/1/2009 - 2/29/2024 
  • SI MCTA Amendment #7
    Effective 9/1/2024 (add UT Dallas and extend to 8/31/2027) 
  • SI MCTA Amendment #6
    Effective 3/1/2024 (extend to 8/31/2024)
  • SI MCTA Amendment #5
    Effective 9/1/2023 (remove Clinical Trials Xpress and extend to 2/29/2024)
  • SI MCTA Amendment #4 (OGC#186751)
    Effective 4/30/2019 (delete UTMDACC)
  • SI MCTA Amendment #3 (OGC#174385)
    Effective 9/1/2018 (add Clinical Trials Xpress and UTRGV; extend to 8/31/2023)
  • SI MCTA Amendment #2 (OGC#152777)
    Effective 4/30/2014 (extend to 4/30/2019)
  • SI MCTA Amendment #1 (OGC#146195)
    Effective 6/5/2013 (name change UTSWMC to UTSW)

Novo Nordisk, Inc.

• Master Clinical Trial Agreement 
  Effective 1/5/2024 - 1/5/2029

Pfizer Inc.

• Amended and Restated Sponsor Initiated Master Clinical Study Agreement (OGC#158907)
  Effective 12/1/2015 - 11/30/2025
  • MCSA Amendment #1 (OGC#180978)
    Effective 12/1/2015 (add Clinical Trials Xpress and UTRGV; extend to 11/30/2025)
• Master Compound Gift Program Agreement(OGC#164445)
  Effective 2/25/2008 (evergreen)

Pharmacyclics LLC 
(now owned by AbbVie Inc.) 

Regeneron Pharmaceuticals, Inc.

• Master Confidentiality Agreement
  Effective 7/5/2018 - 7/5/2028
• Master Clinical Trial Agreement (OGC#183924)
  Effective 2/4/2019 - 2/4/2024
  • MCTA Amendment #1
    Effective 2/4/2024 (extend to 2/4/2025)

Sanofi US Services Inc.

• Master Clinical Trial Agreement
  Effective 4/6/2021 - 4/6/2026
  • MCTA Amendment #1
    Effective 4/8/2024 (add Section 2.7, Safety Reporting)
• Master Mutual Confidentiality Agreement (OGC#185621)
  Effective 10/24/2019 - 10/24/2024
  • MCDA Amendment #1
    Effective 10/24/2024 (add UT Dallas and extend to 10/24/2034)

Statewide Institutional Review Boards (IRBs)

• Five-year Extension
  Effective 7/1/2020 - 6/30/2025
• Restated and Amended IRB Reciprocity Agreement Memorandum of Understanding (OGC#193239)
  Effective 7/1/2015 - 6/30/2025 (toolkit)

UCB Biosciences Inc. / UCB Biopharma SRL

• Master Clinical Trial Agreement (OGC#148258)
  Effective 8/13/2013 - 8/13/2027
  • MCTA Amendment #3 (OGC#200800)
    Effective 4/23/2021 (assign to UCB Biopharma SRL)
  • MCTA Amendment #2 (OGC#195096)
    Effective 08/13/2020 (extend to 8/13/2027)
  • MCTA Amendment #1 (OGC#172049)
    Effective 04/14/2017 (add UTRGV)

UT System 

• Amended and Restated Master Material and Data Transfer Agreement (OGC#187812)
  Effective 3/1/2019 - 7/1/2029
• Master Material Transfer Agreement (OGC#162080)
  Effective 7/1/2018 - 7/1/2025
• Supplemental Conditions to HHS Uniform Terms and Conditions - Governmental Entity Version 3.2 (Version 3.4; November 1, 2021)

 

Terminated Agreements

AbbVie Inc.

• Master Confidential Disclosure Agreement (for the benefit of Clinical Trials Xpress) - (OGC#173117 xref OGC#167233)
  Effective 5/1/2018 - 03/31/2023
  • MCDA Amendment #1
    Effective 3/31/2023 (extend term to 9/30/2023)
  • MCDA Amendment #2
    Effective 10/2/2023 (extend term to 3/31/2024)
• Sponsor Initiated Master Clinical Study Agreement (includes StemCentrx as an Affiliate) - (OGC#167233 xref OGC#173117)
  Effective 10/20/2016 - 10/20/2021 [does not include Pharmacyclics - see Pharmacyclics Master CTA (OGC#165622, OGC#175927)]
  • SI MCSA Amendment #1
    Effective 10/12/2021 (extend term to 3/21/2022)

Astellas Pharma US, Inc. / 
Astellas Pharma Global Development, Inc.

• Restated and Amended Master Clinical Study Agreement
  Effective 4/18/2014 - 10/18/2021
  • MCSA Amendment #2
    Effective 4/18/2021 (extend term to 10/18/2021)
  • MCSA Amendment #1 (OGC#176530)
    Effective 1/28/2020 (include UTRGV)
• Master Clinical Study Agreement (OGC#s 176530, 143504, 141945)
  Effective 4/18/2007 - 4/18/2013
  • MCSA Amendment #1
    Effective 4/17/2012 (extend term to 4/18/2013)

BoehringerIngelheim Pharmaceuticals, Inc.

• Master Confidential Disclosure Agreement (OGC#167258)
  Effective 11/1/2016 - 11/1/2021
• Sponsor Initiated Master Clinical Trial Agreement (OGC#s 165808, 166852)
  Effective 1/25/2016 - 1/25/2021
  • SI MCTA Amendment #1 (OGC#173798)
    ​​​​​Effective 1/25/2016 (add Clinical Trials Xpress and UTRGV)

Citius Pharmaceuticals, Inc.

• Master Confidential Disclosure Agreement
  Effective 06/18/2018 - 06/18/2023

Clinical Trials Xpress (CTX)

• Master Confidential Disclosure Agreement
  Effective 09/24/2018 - 09/24/2023
  (CTX expired as an entity February 2019)

CytoSorbents Corporation

• Master Confidential Disclosure Agreement (OGC#184106)
  Effective 09/05/2018 - 09/05/2023

Genprex, Inc.

• Master Confidential Disclosure Agreement
  Effective 6/1/2018 - 6/1/2023

Genzyme Corporation (see Sanofi)

• Master Clinical Study Agreement (OGC#119767)
  Effective 4/6/2010 - 4/6/2020

GlaxoSmithKline LLC (GSK)

• Restated and Amended Master Clinical Study Agreement (OGC#153657)
  Effective 11/24/2014 - 11/24/2021; Terminated by GSK July 2016

Novartis Pharmaceuticals Corporation

• Investigator-Initiated Master Clinical Trial Agreement 
  (OGC#155726)
  Effective 11/12/2014 - 11/12/2019
• Sponsor-Initiated Master Clinical Trial Agreement (OGC#56990)
  Effective 1/1/2004 - 4/30/2009
  • SI MCTA Amendment #3 
    Effective 1/27/2009 (extend to 4/30/2009)
  • SI MCTA Amendment #2
    Effective 11/27/2006 (amend terms re Article 7G confidential information)
  • SI MCTA Amendment #1
    Effective 4/14/2004 (amend terms re Article 25 biological samples)
• Sponsor-Initiated Master Clinical Trial Agreement (OGC#46423)
  Effective 9/1/1998 - 12/31/2003
  • SI MCTA Amendment #1
    Effective 9/1/2003 (extend to 12/31/2003)

Pfizer Inc.

• Master Investigator Initiated Research Agreement
  Effective 12/1/2015 - 11/30/2020

Pharmacyclics, LLC
(now owned by AbbVie, Inc.)

• Second Master Clinical Study Agreement 
  Effective 1/10/2018 - 1/10/2023 (acquired by AbbVie, Inc.)
• Master Clinical Study Agreement (OGC#165622)
  Effective 3/9/2001 (until terminated by written agreement)

PPD Investigator Services, LLC

• Master Confidentiality and Non-Disclosure Agreement  (OGC#177430)
  Effective 12/14/2017 - 12/31/2022

Statewide Institutional Review Boards (IRBs)

• Restated and Amended IRB Reciprocity Agreement Memorandum of Understanding (OGC#s 157477, 158056 [toolkit])
  Effective 7/1/2015 - 6/30/2020